How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dtacp-ipv-combined-vaccine-tetraxim.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

DTacP-IPV combined vaccine (TETRAXIM™) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DTacP-IPV combined vaccine (TETRAXIM™) (DTacP-IPV combined vaccine (TETRAXIM™)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inactivated vaccine. Area: Immunology.

marketed Combination inactivated vaccine Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3 Immunology Biologic Live · refreshed every 30 min

Target snapshot

DTacP-IPV combined vaccine (TETRAXIM™) (DTacP-IPV combined vaccine (TETRAXIM™)) — Sanofi.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DTacP-IPV combined vaccine (TETRAXIM™) TARGET	DTacP-IPV combined vaccine (TETRAXIM™)	Sanofi	marketed	Combination inactivated vaccine	Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3
GamEvac-Combi (vaccine)	GamEvac-Combi (vaccine)	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	marketed	Combination inactivated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inactivated vaccine class)

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTacP-IPV combined vaccine (TETRAXIM™) — Competitive Intelligence Brief. https://druglandscape.com/ci/dtacp-ipv-combined-vaccine-tetraxim. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab